香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而 產生或因依賴該等內容而引致之任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 CHGHSLimited （以 名稱在香港經營業務） （於百慕達註冊成立之有限公司） 673 （股份代號： ） 截至二零二三年九月三十日止六個月之 中期業績 中國衛生集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹提呈本公司及其附屬 公司（「本集團」）截至二零二三年九月三十日止六個月（「本期間」）之未經審核簡明綜合中 期財務報表。此等未經審核簡明綜合中期財務報表已由本公司之審核委員會審閱。 ...

Financial Performance - For the fiscal year ending March 31, 2023, the company reported revenue of approximately HKD 54,200,000, a decrease of 39% compared to HKD 88,900,000 in the previous year[31]. - The operating profit for the same period was approximately HKD 5,400,000, down from HKD 8,500,000 in the previous year[31]. - The company experienced a significant decline in revenue from its medical device and consumables distribution business due to COVID-19 restrictions, leading to operational losses for its Wuhan subsidiary[33]. - The company reported a loan and interest impairment loss of approximately HKD 4,000,000, an increase from HKD 2,400,000 in the previous year, with a default probability of 20.1%[27]. - The hospital management services segment generated revenue of approximately HKD 21,200,000, an increase from HKD 18,000,000 in the previous year, with an operating loss of HKD 500,000[34]. - The company reported a loss attributable to shareholders of approximately HKD 42,000,000 for the year, compared to a loss of approximately HKD 12,200,000 in the previous year, indicating a significant increase in losses[43]. - The increase in net loss was primarily due to a fair value change loss of approximately HKD 17,700,000 related to the issuance of consideration shares for the acquisition of a subsidiary, compared to a gain of approximately HKD 4,800,000 in the previous year[43]. - The basic loss per share for the year was HKD 0.0986, compared to HKD 0.0296 in the previous year, reflecting a deterioration in financial performance[43]. - For the fiscal year ending March 31, 2023, the company recorded revenue of approximately HKD 76.4 million, a decrease of 29% from HKD 107 million in the previous fiscal year[67]. - Revenue from medical device and consumable distribution and services was approximately HKD 54.2 million, down from HKD 88.9 million in 2022, representing a decline of 39%[67]. - The company achieved a gross profit of approximately HKD 27.2 million, a decrease of 5% compared to HKD 28.7 million in the previous fiscal year[67]. - Hospital operation and management revenue increased to approximately HKD 21.2 million from HKD 18 million in 2022, reflecting a growth of 17.8%[67]. Assets and Liabilities - As of March 31, 2023, the group's cash and cash equivalents amounted to approximately HKD 11,500,000, an increase from HKD 8,500,000 in 2022[9]. - The group's current assets and net current assets were approximately HKD 142,100,000 and HKD 14,900,000, respectively, compared to HKD 137,700,000 and HKD 800,000 in 2022[9]. - The group's liquidity ratio improved to 1.12 as of March 31, 2023, up from 1.0 in 2022[9]. - The asset-to-liability ratio improved to 0.43 as of March 31, 2023, down from 0.61 in 2022[10]. - The group has a payable dividend amount of approximately USD 4,000,000 (around HKD 31,400,000) for redeemable convertible cumulative preferred shares as of March 31, 2023[9]. Acquisitions and Investments - The group successfully acquired Wuhan Mingcheng Wangda Pharmaceutical Co., Ltd. in June 2023, gaining exclusive distribution rights for an eye medication series in mainland China[13]. - The company acquired 51% stake in Wuhan Mingcheng Wangda Pharmaceutical Co., Ltd. for HKD 153,000,000, with payment structured through a combination of promissory notes and share issuance[21]. - The group invested RMB 30,000,000 in Beijing Qihui Zhiyuan Information Technology Partnership, acquiring a 16.6% partnership interest[17]. - The group holds a 20% stake in Trillion Silver Limited, which focuses on the research, development, and manufacturing of healthcare products, including monkeypox virus rapid test kits[20]. Employee and Governance - The total employee cost for the year was approximately HKD 10.2 million, down from HKD 11.2 million in the previous year, indicating a reduction of about 8.9%[82]. - As of March 31, 2023, the company employed 137 staff, an increase from 122 in the previous year, representing a growth of 12.3%[82]. - The board aims for 25% of its members to be female by the end of 2024, currently working towards gender diversity despite being single-gender at present[75]. - The company has established an employee stock option plan, with 19,050,000 options remaining unexercised as of March 31, 2023[82]. - The company’s board is committed to maintaining and establishing sound corporate governance practices to manage overall business risks effectively[182]. - The board held regular meetings throughout the year to formulate overall strategies and monitor business development and financial performance[198]. - The attendance record for board meetings shows that the executive directors attended all meetings, with a 100% attendance rate[199]. - The independent non-executive directors also demonstrated full attendance in their respective meetings, indicating strong governance practices[199]. Market and Future Outlook - The company plans to optimize its product mix and develop new customers and products to seek new growth points in the post-pandemic era[33]. - The company has identified significant growth potential in the healthcare industry due to urbanization and aging population trends in China[41]. - The company has not provided any future performance guidance or outlook in the current reporting period[150]. - The company has not reported any new product or technology developments in the current financial year[150]. - There are no significant acquisitions or market expansions reported in the current financial year[150]. Compliance and Risk Management - The company has complied with relevant laws and regulations significantly during the year, with no major violations reported[123]. - The company has engaged external consultants to review its risk management and internal control systems, with no significant deficiencies found[78]. - The company’s operations are significantly influenced by political, economic, and legal developments in China, which may pose risks to its business and financial performance[95]. - The company has experienced various risks, including operational and financial risks, which may impact its financial performance and future outlook[120]. - The company is committed to strict adherence to relevant laws and regulations in all its business dealings[198]. Shareholder Information - The total shareholding of Mr. Zhang Fan is 118,107,400 shares, representing 24.66% of the issued shares[134]. - Major shareholder Treasure Wagon Limited holds 116,000,000 shares, accounting for 24.22% of the total issued shares[140]. - The company completed a placement of convertible bonds totaling HKD 40,000,000, which can be converted into 40,000,000 shares at an adjusted conversion price of HKD 1.00 per share[144]. - The net proceeds from the placement amounted to approximately HKD 38,800,000, with HKD 13,800,000 allocated for general working capital and HKD 25,000,000 reserved for potential business development and investments[145]. - The company did not recommend any dividend distribution for the year ended March 31, 2023, consistent with the previous year[124]. - As of March 31, 2023, the company had no reserves available for distribution or physical distribution according to the Bermuda Companies Act 1981[127].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等 內容而引致之任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 CHG HS Limited （以 名稱在香港經營業務） （於百慕達註冊成立之有限公司） 673 （股份代號： ） 截至二零二三年三月三十一日止年度之全年業績 中國衛生集團有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此公佈本公司及其附屬公司 （「本集團」）截至二零二三年三月三十一日止年度之綜合業績，連同截至二零二二年三月三十一日 止年度之比較數字如下： 綜合損益表 截至三月三十一日 止年度 二零二三年 二零二二年 附註 千港元 千港元 收入 5 76,414 107,025 銷售貨物╱提供服務之成本 (49,222) (78,336) ...

Financial Performance - The company recorded revenue of approximately HKD 107 million for the fiscal year ending March 31, 2022, representing a 22% increase from HKD 87.9 million in the previous fiscal year[11]. - Revenue from the medical device and consumables distribution and services amounted to approximately HKD 88.9 million, up 29% from HKD 68.8 million in the previous year[14]. - The company reported a gross profit of approximately HKD 28.7 million, an increase of 10% compared to HKD 26 million in the previous fiscal year[11]. - The company incurred a loss attributable to shareholders of approximately HKD 12.2 million, compared to a loss of HKD 7.7 million in the previous fiscal year[12]. - The group recorded revenue of approximately HKD 18,000,000 from the operation of Anping Kangrong Hospital, an increase from HKD 15,400,000 in the previous year[24]. - The group incurred an operating loss of approximately HKD 2,500,000 from Anping Kangrong Hospital, compared to HKD 2,300,000 in the previous year[24]. Investments and Acquisitions - The company increased its stake in Wuhan Magrez from 51% to 87.75% to strengthen its core competitiveness in the cardiovascular device distribution business[16]. - The acquisition of 60% of Beijing Youkang's equity was completed, focusing on the distribution of medical equipment in Beijing and surrounding areas, which are among the most promising regions in China[17]. - The group completed the acquisition of 75% equity in Longhuang Limited, which owns 49% of Wuhan Magrez, for a total consideration of HKD 14,600,000[32]. - The acquisition of Beijing Youkang involved an investment of RMB 1,800,000 (approximately HKD 2,160,000) by the company and its subsidiary, with existing owners investing RMB 1,200,000 (approximately HKD 1,440,000)[37]. Cash and Assets - As of March 31, 2022, the company's cash and cash equivalents amounted to approximately HKD 8,500,000, an increase from HKD 4,600,000 in the previous year[47]. - The company's current assets and net current assets were approximately HKD 137,700,000 and HKD 800,000, respectively, with a current ratio of 1.0, down from 1.4 in the previous year[47]. - The company has bank loans valued at RMB 6,500,000 (approximately HKD 8,100,000) as of March 31, 2022, compared to RMB 3,000,000 (approximately HKD 3,600,000) in the previous year[48]. - The company's debt-to-equity ratio was 0.61 as of March 31, 2022, compared to 0.33 in the previous year[48]. Employee and Compensation - As of March 31, 2022, the group employed 122 employees, an increase from 116 in the previous year[53]. - Total employee costs amounted to approximately HKD 12 million, down from HKD 18.4 million in the previous year, with director remuneration and share-based payment expenses around HKD 800,000[53]. - The group continues to review employee compensation packages based on market conditions and individual performance[53]. - No stock options were granted during the year, and 22,500,000 stock options expired, leaving 243,400,000 unexercised options as of March 31, 2022[53]. Corporate Governance - The board of directors confirmed compliance with the corporate governance code throughout the year, with some disclosed deviations[128]. - The group has appointed financial and legal advisors to ensure compliance with legal and regulatory requirements[135]. - The company has established a remuneration committee responsible for reviewing and approving the remuneration policies for all directors and senior management, with specific details disclosed in the financial statements[141]. - The audit committee has reviewed the financial statements for the year ending March 31, 2022, and discussed internal controls and financial reporting matters[152]. - The board has established a risk management and internal control system to protect shareholders' interests and the group's assets, with annual evaluations of its effectiveness[157]. Environmental, Social, and Governance (ESG) - The environmental, social, and governance (ESG) report aims to highlight the group's performance in these areas to assist stakeholders in understanding its sustainable development practices[173]. - The group has identified key ESG issues through stakeholder engagement and prioritization, focusing on high, medium, and low importance categories for strategic planning[189]. - The main source of greenhouse gas emissions for the group is electricity consumption from office equipment, with minimal direct emissions from operations[195]. - The group encourages employees to use public transport or carpooling to reduce air pollution emissions[194]. - In 2022, the total greenhouse gas emissions decreased to 284 tons from 421 tons in 2021, representing a reduction of approximately 32.5%[196]. Risks and Compliance - The company acknowledges various risks and uncertainties, including business, operational, and financial risks that may impact its financial performance and future prospects[74]. - The company has confirmed compliance with relevant laws and regulations in its operations in China and Hong Kong, with no major violations reported for the year[77]. - The group prioritizes compliance with applicable laws and regulations as a key concern for stakeholders, particularly government and regulatory bodies[187]. - The company has taken sufficient measures to ensure corporate governance standards meet or exceed regulatory requirements[140].

China Health Group Limited 中國衛生集團有限公司 （以 CHG HS Limited 名稱在香港經營業務 ) ( 於百慕遂註冊成立之有限公司 ) 香港爵合交易所上市(股份代號：673) 20 中 期 報 告 中國衛生集團有限公司 2021年中期報告 1 | --- | --- | |-----------------------------------------------|----------------------------------------------------------| | | | | 公司資料 | 主要往來銀行 | | 董事 | 東亞銀行有限公司 | | 執行董事 | 香港 | | 張凡先生 鍾浩先生 | 德輔道中 10 號 核數師 | | 非執行董事 | 開元信德會計師事務所有限公司 香港尖沙咀 | | 邢勇先生 黃連海先生 | 天文臺道 8 號 10 樓 | | 王景明先生 | 法律顧問 | | | | | 獨立非執行董事 | 眾達國際法律事務所 | | 蔣學俊先生 杜嚴華先生 | 香港 皇后大道中 15 號 | | 賴亮全先生 | 置地廣場 公爵大廈 ...

China Health Group Limited 中國衛生集團有限公司 （以 CHG HS Limited 名稱在香港經營業務） （於百慕達註冊成立之有限公司） 香港聯合交易所上市(股份代號︰673) 年 報 2 021 中國衛生集團有限公司 2021年年報 目錄 | --- | |------------------------------| | | | 公司資料 | | 主席報告書 | | 管理層討論及分析 | | 董事及高層管理人員之履歷詳情 | | 董事會報告書 | | 企業管治報告 | | 環境、社會及管治報告 | | 獨立核數師報告 | | 綜合損益表 | | 綜合損益及其他全面收益表 | | 綜合財務狀況表 | | 綜合權益變動表 | | 綜合現金流量表 | | 綜合財務報表附註 | | | 2 3 4 11 15 28 36 44 51 52 53 55 57 59 財務概要 132 1 中國衛生集團有限公司 2021年年報 公司資料 | --- | --- | |------------------------|-------------------------------------- ...

China Health Group Limited 中國衛生集團有限公司 （以 CHG HS Limited 名稱在香港經營業務） （於百慕達註冊成立之有限公司） 香港聯合交易所上市(股份代號︰673) 2 020 年 報 中國衛生集團有限公司 2020年年報 目錄 | --- | --- | |------------------------------|-------| | | | | 公司資料 | | | 主席報告書 | | | 管理層討論及分析 | | | 董事及高層管理人員之履歷詳情 | | | 董事會報告書 | | | 企業管治報告 | | | 獨立核數師報告 | | | 綜合損益表 | | | 綜合損益及其他全面收益表 | | | 綜合財務狀況表 | | | 綜合權益變動表 | | | 綜合現金流量表 | | | 綜合財務報表附註 | | | 財務概要 | | 2 3 4 17 22 36 44 52 53 54 56 58 60 140 1 中國衛生集團有限公司 2020年年報 公司資料 | --- | --- | |------------------------|------------ ...

China Health Group Limited 中國衛生集團有限公司 ( 以 CHG HS Limited 名稱在香港經營業務 ) ( 於百募遂註冊成立之有限公司 ) 香港聯合交易所上市(股份代號：673) 中國衛生集團有限公司 2019年中期報告 | --- | --- | |--------------------------------------------------------------------------------------------|---------------------------------------------------------------| | | | | 公司資料 | 主要往來銀行 | | 董事 | 東亞銀行有限公司 | | 執行董事 | 香港 德輔道中 10 號 | | 張凡先生 鍾浩先生 | 核數師 | | 王景明先生 翁羽先生 非執行董事 | 開元信德會計師事務所有限公司 香港尖沙咀 天文臺道 8 號 10 樓 | | 邢勇先生 | 法律顧問 | | 黃連海先生 張達威先生 （於二零一九年六月四日委任） 王咏明先生 （於二零一九年六月四日委任） | ...

China Health Group Limited 中國衛生集團有限公司 （以 CHG HS Limited 名稱在香港經營業務） （於百慕達註冊成立之有限公司） 香港聯合交易所上市(股份代號︰673) 2 019 年 報 By 中國衛生集團有限公司 2019年年報 公司資料 2 主席報告書 3 管理層討論及分析 4 董事及高層管理人員之履歷詳情 13 董事會報告書 19 企業管治報告 28 獨立核數師報告 37 綜合損益表 45 綜合損益及其他全面收益表 46 綜合財務狀況表 47 綜合權益變動表 49 綜合現金流量表 51 綜合財務報表附註 53 財務概要 127 物業權益表 128 目錄 1 中國衛生集團有限公司 2019年年報 公司資料 | --- | --- | |---------------------------------------|----------------------------------------------------------------| | | | | 董事會 | 主要往來銀行 | | 執行董事 | 東亞銀行有限公司 | | 張凡先生 | 香港 | | 鍾浩先生 ...